Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311

- Ackland, Stephen P., Gebski, V., Forbes, J. F., Coates, A. S., Zdenkowski, N., Wilson, A., Green, M., Tees, S., Dhillon, H., Van Hazel, G., Levi, J., Simes, R. J.

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT

- Regan, M. M., Walley, B. A., Spazzapan, S., Parmer, V., Ruhstaller, T., Abdi, E. A., Gelber, R. D., Coates, A. S., Goldhirsch, A., Pagani, O., Francis, P. A., Fleming, G. F., Lang, I., Gomez, H. L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

- Zdenkowski, N., Forbes, J. F., Mann, G. B., Coates, A. S., Gebski, V., Davies, L., Thornton, R., Reaby, L., Cuzick, J., Green, M., Boyle, F. M., Kannourakis, G., Gill, P. G., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Campbell, I.

Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the primary therapy of early breast cancer 2015

- Coates, A. S., Winer, E. P., Bergh, Jonas, Bonnefoi, Hervé, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Ejlertsen, Bent, Goldhirsch, A., Forbes, John F., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., André, Fabrice, Baselga, José

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

- Huober, J., Cole, B. F., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I.

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013

- Goldhirsch, A., Winer, E. P., Bonnefoi, Hervé, Bretel-Morales, Denisse, Burstein, Harold, Cardoso, Fatima, Castiglione-Gertsch, Monica, Colleoni, Marco, Costa, Alberto, Curigliano, Giuseppe, Davidson, Nancy E., Leo, Angelo Di, Coates, A. S., Ejlertsen, Bent, Forbes, John F., Gelber, Richard D., Gnat, Michael, Goldhirsch, Aron, Goodwin, Pamela, Goss, Paul E., Harris, Jay R., Hayes, Daniel F., Hudis, Clifford A., Gelber, R. D., Ingle, James N., Jassem, Jacek, Jiang, Zefei, Karlsson, Per, Loibl, Sibylle, Morrow, Monica, Namer, Moise, Osborne, C. Kent, Partridge , Ann H., Penault-Llorca, Fréderiqué, Piccart-Gebhart, M., Perou, Charles M., Piccart-Gebhart, Martine, Pritchard, Kathleen I., Rutgers, Emiel J. T., Sedlmayer, Felix, Semiglazov, Vladimir, Shao, Zhi-Ming, Smith, Ian, Thürlimann, Beat, Toi, Masakazu, Tutt, Andrew, Untch, Michael, Viale, Giuseppe, Watanabe, Toru, Wilcken, Nicholas, Winer, Eric P., Wood, William C., Senn, H. - J., Albain, Kathy S., André, Fabrice, Bergh, Jonas

Which patients benefit most from adjuvant aromatase inhibitors?: results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

- Viale, G., Regan, M. M., Lang, I., Thürlimann, B., Mouridsen, H., Mauriac, L., Gelber, R. D., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S., Dell'Orto, P., Mastropasqua, M. G., Maiorano, E., Rasmussen, B. B., MacGrogan, G., Forbes, J. F., Paridaens, R. J., Colleoni, M.

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

- Rabaglio, M., Sun, Z., Colleoni, M., Pienkowski, T., Nogaret, J. -M., Láng, I., Smith, I., Gelber, R. D., Goldhirsch, A., Coates, A. S., Price, K. N., Castiglione-Gertsch, M., Hawle, H., Thürlimann, B., Mouridsen, H., Campone, M., Forbes, J. F., Paridaens, R. J.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer

- Bernhard, J., Zahrieh, D., Green, M. D., Colleoni, M., Gelber, R. D., Castiglione-Gertsch, M., Price, K. N., Goldhirsch, A., Coates, A. S., Zhang, J. J., Martinelli, G., Basser, R., Hurny, C., Forbes, J. F., Aebi, S., Yeo, W., Thurlimann, B.